KCT0006479已完成未知
A double-blind placebo-controlled, dose dependent pilot study to evaluate the safety and efficacy of cognitive enhancing function of GEF as a white ginseng non-aqueous alcohol extract
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 50?(Year) 至 85?(Year)（—）
- 性别
- All
入选标准
- •1) Those aged 50 to 85 years of age who complain of subjective memory impairment
- •2) Those with a K-MMSE score of 23 or higher
- •3) Those who do not interfere with daily life due to cognitive decline
- •4) Those who consented to participate in the clinical trial before the start of this study and signed an informed consent
排除标准
- •(1) Those who are consuming ginseng or health functional food containing ginseng ingredients
- •(2) Those with allergies or hypersensitivity to ginseng
- •(3) Those with clinically significant liver disease or renal disease, with ALT, AST, or bilirubin at least 3 times the upper limit of normal
- •(4) Those who have blood creatinine>2.0mg/Dl (176.7µmol/L) or need kidney dialysis
- •(5) Those who have undergone surgery that may interfere with food absorption or are unable to administer oral administration
- •(6) Those receiving treatment for major psychiatric disorders such as bipolar disorder and schizophrenia
- •(7) Those diagnosed with dementia at the hospital
- •(8) The illiterate
- •(9) Those who have taken anti-dementia drugs within 4 weeks of the start of the human application test, or have administered drugs and health functional foods that may affect memory and cognitive function
- •(10) Alcoholic or drug addicts
- •(11) Those receiving other test drugs related to cognitive function improvement
- •(12) Pregnant or prospective pregnant women
- •(13) Those who participated in other human application tests or clinical trials within one month of the visit
- •(14) Those who are judged to be inappropriate for the researcher to participate
研究者
相似试验
未知
2 期
A phase II/III study of TAC-202 in patients with chronic idiopathic urticariaPatients with Chronic idiopathic urticariaJPRN-jRCT2080222523Taiho Pharmaceutical Co., Ltd.300
进行中（未招募）
1 期
Dose-ranging study to assess the efficacy, safety, and tolerability of SAR440340 (anti-IL-33 mAb) in patients with moderate-to-severe asthmaMedDRA version: 20.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersAsthmaEUCTR2019-003751-10-ITSANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT1,120
已完成
1 期
A randomized, double-blind, placebo-controlled dose-escalation study of AND017 capsules in healthy subjects following oral single and multiple dose administratioAnaemiaBlood - AnaemiaACTRN12620000725965BalanceBio Pty Ltd78
进行中（未招募）
1 期
Dose-ranging study to assess the efficacy, safety, and tolerability of SAR440340 (anti-IL-33 mAb) in patients with moderate-to-severe asthmaMedDRA version: 20.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersAsthmaEUCTR2019-003751-10-ESSanofi-Aventis Recherche & Developpement1,120
已完成
1 期
Safety, tolerability, pharmacokinetics and pharmacodynamics of KNS366Healthy volunteers. The intended indication for the product under development is damage to secondary organs during a systemic inflammatory response.ISRCTN10496020Kynos Therapeutics Ltd40